AU5759899A - Hydroxyflavone derivatives as tau protein kinase 1 inhibitors - Google Patents

Hydroxyflavone derivatives as tau protein kinase 1 inhibitors

Info

Publication number
AU5759899A
AU5759899A AU57598/99A AU5759899A AU5759899A AU 5759899 A AU5759899 A AU 5759899A AU 57598/99 A AU57598/99 A AU 57598/99A AU 5759899 A AU5759899 A AU 5759899A AU 5759899 A AU5759899 A AU 5759899A
Authority
AU
Australia
Prior art keywords
inhibitors
protein kinase
tau protein
hydroxyflavone derivatives
hydroxyflavone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57598/99A
Inventor
Ryoichi Ando
Keiichi Aritomo
Toshiyuki Honda
Tetsuo Jikihara
Rie Kawamoto
Kenichi Saito
Aya Shoda
Kazutoshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Publication of AU5759899A publication Critical patent/AU5759899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
AU57598/99A 1998-09-24 1999-09-24 Hydroxyflavone derivatives as tau protein kinase 1 inhibitors Abandoned AU5759899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10/270262 1998-09-24
JP27026298 1998-09-24
PCT/JP1999/005223 WO2000017184A1 (en) 1998-09-24 1999-09-24 Hydroxyflavone derivatives as tau protein kinase 1 inhibitors

Publications (1)

Publication Number Publication Date
AU5759899A true AU5759899A (en) 2000-04-10

Family

ID=17483811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57598/99A Abandoned AU5759899A (en) 1998-09-24 1999-09-24 Hydroxyflavone derivatives as tau protein kinase 1 inhibitors

Country Status (7)

Country Link
EP (1) EP1115718A1 (en)
JP (1) JP2002526488A (en)
KR (1) KR20010079922A (en)
CN (1) CN1326450A (en)
AU (1) AU5759899A (en)
CA (1) CA2345311A1 (en)
WO (1) WO2000017184A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
CA2495661C (en) * 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
WO2006045096A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
PT2118074E (en) 2007-02-01 2014-03-20 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
AU2008257437A1 (en) * 2007-02-14 2008-12-04 Mars, Incorporated Neurogenic compounds
CA2711103C (en) 2008-06-26 2016-08-09 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
KR101892987B1 (en) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
JP5992049B2 (en) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション Oral immediate release formulations for substituted quinazolinones
ES2648154T3 (en) * 2012-01-26 2017-12-28 Daiichi Sankyo Company, Limited Chromone derivative that has an osteogenesis promoter effect
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (en) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． Novel heterocyclic compounds as bromodomain inhibitors
JP6468549B2 (en) * 2015-01-30 2019-02-13 国立大学法人金沢大学 Benzothiophene derivatives with anticancer activity
CN107530356A (en) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 For treating the composition and treatment method of complement-associated disease
JP6416828B2 (en) * 2016-06-23 2018-10-31 株式会社レーネ Tau protein aggregation inhibitor
CN109111400B (en) * 2017-06-23 2020-10-16 杭州百诚医药科技股份有限公司 Preparation and application of phenylquinolinone and flavonoid derivatives
CN108299365B (en) * 2018-01-31 2021-08-06 中南大学 Flavone derivative and application thereof
GB202104134D0 (en) * 2021-03-24 2021-05-05 Floratek Pharma Ag Compounds and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1362782A (en) * 1970-08-26 1974-08-07 Fisons Ltd Tetrazole derivatives
CA2116460A1 (en) * 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
CA2182932A1 (en) * 1995-08-10 1997-02-11 Koju Watanabe Chromone derivative, process for preparing same and pharmaceutical composition
JPH09301915A (en) * 1996-05-08 1997-11-25 Sankyo Co Ltd Flavone and naphthalene derivative
FR2753969B1 (en) * 1996-09-27 1998-10-30 Adir NOVEL FLAVON DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Also Published As

Publication number Publication date
CA2345311A1 (en) 2000-03-30
KR20010079922A (en) 2001-08-22
JP2002526488A (en) 2002-08-20
EP1115718A1 (en) 2001-07-18
WO2000017184A1 (en) 2000-03-30
CN1326450A (en) 2001-12-12

Similar Documents

Publication Publication Date Title
AU5759899A (en) Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU7631496A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU7726898A (en) Pyrazole derivatives as p38 kinase inhibitors
AU5324996A (en) Protein kinase c inhibitors
AU8689298A (en) Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
IL141866A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU4956297A (en) Raf kinase inhibitors
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
AU8681798A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU8681698A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU7289696A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2002231166A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002234047A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
AU5283999A (en) Substituted pyrazole derivatives
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU4791797A (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
AU2001232799A1 (en) Protein c derivatives
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase